NEW
YORK, May 10, 2022 /PRNewswire/ -- Weiss
Law, a national shareholders' rights law firm, is investigating
possible false claims, deceptive accounting and reporting
practices, breaches of fiduciary duty, and violations of the
federal securities laws by the Board of Directors and certain
Company officers of Emergent BioSolutions Inc. (NYSE: EBS)
("Emergent" or the "Company"). According to a final report expected
to be released today after a year-long investigation by the House
of Representatives' Select Subcommittee on the Coronavirus Crisis,
the Company, hired to produce hundreds of millions of coronavirus
vaccine doses, hid from US Food and Drug Administration ("FDA")
inspectors evidence of quality control problems in February 2021- six weeks before it alerted
federal officials that 15 million doses were contaminated.
If you own Emergent shares and wish to discuss
this investigation, or share information which you have, or if you
have any questions concerning this notice or your rights or
interests, visit our website
at
https://www.weisslaw.co/news-and-cases/ebs
Or
please contact:
Josh Rubin,
Esq stocks@weisslaw.co
(212)
682-3025.
There is no cost or obligation to you.
A report released by the House and the Select Subcommittee on
the Coronavirus Crisis found that nearly 400 million doses of
coronavirus vaccine manufactured by Emergent were destroyed "due to
poor quality control," including about 240 million doses in late
2020 and early 2021. The report, based on internal company
emails, documents and interviews, expounds on Emergent executives'
worries about deficiencies in the Company's quality control systems
at its Bayview plant in Baltimore,
MD.
A former Emergent executive acknowledged in an email that he had
alerted other senior executives "for a few years" about problems at
the plant, writing that "room to improve is a huge understatement."
And, in advance of a visit to the plant by FDA officials in
September 2020 in which the agency
noted deficiencies, a senior quality director warned executives
that it would be critical to convince the agency that rapid
improvements were underway. "We are not in full compliance
yet- BUT- we are making batches NOW," the director wrote.
In late March 2021, Emergent
notified the Department of Health and Human Services about the
contaminated doses. That culminated with the Biden
administration terminating Emergent's vaccine production
contract in November 2021.
If you own EBS shares and wish to discuss this investigation,
please visit our website at
https://www.weisslaw.co/news-and-cases/ebs or contact Josh Rubin at stocks@weisslaw.co or (212)
682-3025. There is no cost or obligation to you.
Weiss Law has litigated hundreds of stockholder class and
derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for
defrauded clients. For more information about the firm,
please go to: http://www.weisslaw.co
View original content to download
multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-weiss-law-investigates-emergent-biosolutions-inc-301544222.html
SOURCE Weiss Law